Table 1.
Characteristic | Distribution |
---|---|
Demographics | |
Mean age, y (SD) | 56.1 (5.5) |
Race, % | |
Caucasian | 75.0 |
African American | 25.0 |
Clinical characteristics, % | |
FibroSURE-ActiTest | |
F0–F3 | 61.6 |
F3/F4–F4 | 38.4 |
Necroinflammatory | |
A0–A2 | 67.4 |
A2/3–A3 | 32.6 |
HCV genotype | |
1 (unspecified) | 3.6 |
1a | 70.1 |
1b | 26.3 |
Overall treatment ineligible, % | 36.0 |
Reasons for treatment ineligibility, % | |
Physical comorbidity | 19.5 |
Coronary artery disease | 2.6 |
Other cardiac conditions | 0.3 |
COPD | 3.2 |
ESRD | 0.0 |
Cancer | 4.5 |
Decompensated cirrhosis | 4.5 |
Othera | 9.7 |
Mental comorbidity | 19.2 |
Current drug/alcohol use | 13.0 |
Depression | 10.1 |
Other psychiatric diagnosesb | 0.6 |
Other barriers | 8.4 |
Noncompliance with evaluation | 1.9 |
Homelessness | 0.3 |
Noninterest in treatment | 3.6 |
Failed previous treatment | 2.6 |
Eventually treated, % | 11.0 |
COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease.
Included were anemia, awaiting hip surgery, cerebrovascular disease, colitis, diabetes, glaucoma, hyperthyroidism, hypothyroidism, neutropenia, obesity, pancytopenia, peripheral vascular disease, retinal vein occlusion, seizures, suspicious mass, suspicious lesions, thrombosis, and thrombocytopenia.
Included memory issues.